UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2026
or
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________.
Commission File Number: 0-12305
KORU MEDICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
13-3044880 |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| |
|
| 100 Corporate Drive, Mahwah, New Jersey |
07430 |
| (Address of principal executive offices) |
(Zip Code) |
(845) 469-2042
(Registrant’s telephone number, including area
code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common stock, $0.01 par value |
KRMD |
The Nasdaq Stock Market |
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
[X] Yes [_] No
Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X] Yes [_]
No
Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large
accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
| |
Large accelerated filer [_] |
Accelerated filer [_] |
| |
Non-accelerated filer [X] |
Smaller reporting company [X] |
| |
|
Emerging growth company [_] |
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. [_]
Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act). [_] Yes [X] No
As of May 6, 2026, 45,933,000 shares of common stock, $0.01 par value
per share, were outstanding, which excludes 4,018,526 shares of treasury stock.
KORU MEDICAL SYSTEMS, INC.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026
TABLE OF CONTENTS
| |
|
PAGE |
| |
|
|
| PART I. FINANCIAL INFORMATION |
| |
|
|
| ITEM 1. |
Condensed Financial Statements (Unaudited) |
3 |
| |
|
|
| |
Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025 |
3 |
| |
|
|
| |
Statements of Operations (Unaudited) for the three months ended March 31, 2026 and 2025 |
4 |
| |
|
|
| |
Statements of Cash Flows (Unaudited) for the three months ended March 31, 2026 and 2025 |
5 |
| |
|
|
| |
Statements of Stockholders’ Equity (Unaudited) for the three months ended March 31, 2026 and 2025 |
6 |
| |
|
|
| |
Notes to Financial Statements |
7 |
| |
|
|
| ITEM 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
13 |
| |
|
|
| ITEM 3. |
Quantitative and Qualitative Disclosures About Market Risk |
16 |
| |
|
|
| ITEM 4. |
Controls and Procedures |
17 |
| |
|
|
| PART II. OTHER INFORMATION |
| |
|
|
| ITEM 1A. |
Risk Factors |
17 |
| |
|
|
| ITEM 6. |
Exhibits |
17 |
| |
|
|
| |
Signatures |
18 |
- 2 -
Table of Contents
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
KORU MEDICAL SYSTEMS, INC.
BALANCE SHEETS
| |
|
|
|
|
|
| |
|
March 31, |
|
December 31, |
|
| |
|
2026 |
|
2025 |
|
| |
|
(UNAUDITED) |
|
|
|
| |
|
|
|
|
|
|
|
| ASSETS |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| CURRENT ASSETS |
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
8,767,774 |
|
$ |
8,872,212 |
|
| Accounts receivable |
|
|
5,982,536 |
|
|
6,209,950 |
|
| Inventory, net |
|
|
4,476,304 |
|
|
3,678,131 |
|
| Other receivables |
|
|
335,206 |
|
|
319,955 |
|
| Prepaid expenses |
|
|
1,026,614 |
|
|
908,542 |
|
| TOTAL CURRENT ASSETS |
|
|
20,588,434 |
|
|
19,988,790 |
|
| Property and equipment, net |
|
|
4,335,882 |
|
|
4,471,386 |
|
| Intangible assets, net of accumulated amortization of $545,302 and $527,949 as of March 31, 2026 and December 31, 2025, respectively |
|
|
711,211 |
|
|
684,841 |
|
| Operating lease right-of-use assets |
|
|
2,857,341 |
|
|
2,956,192 |
|
| Other assets |
|
|
98,970 |
|
|
98,970 |
|
| TOTAL ASSETS |
|
$ |
28,591,838 |
|
$ |
28,200,179 |
|
| |
|
|
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| CURRENT LIABILITIES |
|
|
|
|
|
|
|
| Accounts payable |
|
$ |
2,635,701 |
|
$ |
2,267,473 |
|
| Accrued expenses |
|
|
5,271,100 |
|
|
4,828,830 |
|
| Other liabilities |
|
|
11,068 |
|
|
27,722 |
|
| Accrued payroll and related taxes |
|
|
385,890 |
|
|
531,972 |
|
| Financing lease liability |
|
|
126,323 |
|
|
124,913 |
|
| Operating lease liability |
|
|
421,727 |
|
|
413,448 |
|
| TOTAL CURRENT LIABILITIES |
|
|
8,851,809 |
|
|
8,194,358 |
|
| Financing lease liability, net of current portion |
|
|
46,560 |
|
|
78,675 |
|
| Operating lease liability, net of current portion |
|
|
2,771,115 |
|
|
2,879,224 |
|
| TOTAL LIABILITIES |
|
|
11,669,484 |
|
|
11,152,257 |
|
| |
|
|
|
|
|
|
|
| STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
| Common stock, $0.01 par value, 75,000,000 shares authorized, 49,933,502 and 49,790,934 shares issued 46,133,000 and 46,370,432 shares outstanding as of March 31, 2026, and December 31, 2025, respectively |
|
|
499,335 |
|
|
497,909 |
|
| Additional paid-in capital |
|
|
54,795,722 |
|
|
52,449,339 |
|
| Treasury stock, 3,818,526 and 3,438,526 shares as of March 31, 2026 and December 31, 2025, respectively, at cost |
|
|
(5,548,793 |
) |
|
(3,882,494 |
) |
| Accumulated deficit |
|
|
(32,823,910 |
) |
|
(32,016,832 |
) |
| TOTAL STOCKHOLDERS’ EQUITY |
|
|
16,922,354 |
|
|
17,047,922 |
|
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
28,591,838 |
|
$ |
28,200,179 |
|
The accompanying notes are an integral part of these
financial statements.
- 3 -
Table of Contents
KORU MEDICAL SYSTEMS, INC.
STATEMENTS OF OPERATIONS
(UNAUDITED)
| |
|
|
|
|
|
|
|
| |
|
Three Months Ended |
|
| |
|
March 31, |
|
| |
|
2026 |
|
2025 |
|
| |
|
|
|
|
|
|
|
| NET REVENUES |
|
$ |
11,764,624 |
|
$ |
9,635,075 |
|
| Cost of goods sold |
|
|
4,533,235 |
|
|
3,588,740 |
|
| Gross Profit |
|
|
7,231,389 |
|
|
6,046,335 |
|
| |
|
|
|
|
|
|
|
| OPERATING EXPENSES |
|
|
|
|
|
|
|
| Selling, general and administrative |
|
|
6,582,178 |
|
|
5,959,374 |
|
| Research and development |
|
|
1,316,603 |
|
|
1,114,609 |
|
| Depreciation and amortization |
|
|
197,531 |
|
|
217,357 |
|
| Total Operating Expenses |
|
|
8,096,312 |
|
|
7,291,340 |
|
| |
|
|
|
|
|
|
|
| Net Operating Loss |
|
|
(864,923 |
) |
|
(1,245,005 |
) |
| |
|
|
|
|
|
|
|
| Non-Operating Income/(Expense) |
|
|
|
|
|
|
|
| Gain/(Loss) on currency exchange |
|
|
(23,150 |
) |
|
5,588 |
|
| Interest income, net |
|
|
80,995 |
|
|
73,180 |
|
| TOTAL OTHER INCOME |
|
|
57,845 |
|
|
78,768 |
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Income Tax Refund (Expense) |
|
|
— |
|
|
— |
|
| |
|
|
|
|
|
|
|
| NET LOSS |
|
$ |
(807,078 |
) |
$ |
(1,166,237 |
) |
| |
|
|
|
|
|
|
|
| NET LOSS PER SHARE |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Basic & Diluted |
|
$ |
(0.02 |
) |
$ |
(0.03 |
) |
| |
|
|
|
|
|
|
|
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Basic & Diluted |
|
|
46,364,905 |
|
|
45,981,826 |
|
The accompanying notes are an integral part of these
financial statements.
- 4 -
Table of Contents
KORU MEDICAL SYSTEMS, INC.
STATEMENTS OF CASH FLOWS
(UNAUDITED)
| |
|
|
|
|
|
|
| |
|
For the
Three Months Ended |
|
| |
|
March 31, |
|
| |
|
2026 |
|
2025 |
|
| |
|
|
|
|
|
|
|
| CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
| Net Loss |
|
$ |
(807,078 |
) |
$ |
(1,166,237 |
) |
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
| Stock-based compensation expense and warrant expense |
|
|
681,510 |
|
|
697,590 |
|
| Depreciation and amortization |
|
|
197,531 |
|
|
217,357 |
|
| Non-cash leasing charges |
|
|
(979 |
) |
|
— |
|
| Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
| Accounts receivable |
|
|
227,414 |
|
|
(228,661 |
) |
| Inventory |
|
|
(798,173 |
) |
|
(474,977 |
) |
| Prepaid expenses and other assets |
|
|
(133,323 |
) |
|
(8,094 |
) |
| Other liabilities |
|
|
(16,655 |
) |
|
80,828 |
|
| Accounts payable |
|
|
368,228 |
|
|
363,608 |
|
| Accrued payroll and related taxes |
|
|
(146,081 |
) |
|
227,316 |
|
| Accrued expenses |
|
|
442,269 |
|
|
53,803 |
|
| NET CASH FROM/(USED IN) OPERATING ACTIVITIES |
|
|
14,663 |
|
|
(237,467 |
) |
| |
|
|
|
|
|
|
|
| CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
| Purchases of property and equipment |
|
|
(46,163 |
) |
|
(443,438 |
) |
| Purchases of intangible assets |
|
|
(43,722 |
) |
|
(3,400 |
) |
| NET CASH USED IN INVESTING ACTIVITIES |
|
|
(89,885 |
) |
|
(446,838 |
) |
| |
|
|
|
|
|
|
|
| CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
| Payments on insurance finance indebtedness |
|
|
— |
|
|
(133,973 |
) |
| Payments on finance lease liability, net of asset |
|
|
(29,216 |
) |
|
(26,835 |
) |
| NET CASH USED IN FINANCING ACTIVITIES |
|
|
(29,216 |
) |
|
(160,808 |
) |
| |
|
|
|
|
|
|
|
| NET DECREASE IN CASH AND CASH EQUIVALENTS |
|
|
(104,438 |
) |
|
(845,113 |
) |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
|
|
8,872,212 |
|
|
9,580,947 |
|
| CASH AND CASH EQUIVALENTS, END OF PERIOD |
|
$ |
8,767,774 |
|
$ |
8,735,834 |
|
| |
|
|
|
|
|
|
|
| Supplemental Information |
|
|
|
|
|
|
|
| Cash paid during the periods for: |
|
|
|
|
|
|
|
| Interest |
|
$ |
2,155 |
|
$ |
5,385 |
|
The accompanying notes are an integral part of these
financial statements.
- 5 -
Table of Contents
KORU MEDICAL SYSTEMS, INC.
STATEMENTS OF STOCKHOLDERS’ EQUITY
(UNAUDITED)
Three Months Ended March 31, 2026
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
Additional |
|
|
|
|
|
Total |
|
| |
|
Common Stock |
|
Paid-in |
|
Accumulated |
|
Treasury |
|
Stockholders’ |
|
| |
|
Shares |
|
Amount |
|
Capital |
|
Deficit |
|
Stock |
|
Equity |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BALANCE, DECEMBER 31, 2025 |
|
49,790,934 |
|
$ |
497,909 |
|
$ |
52,449,339 |
|
$ |
(32,016,832 |
) |
$ |
(3,882,494 |
) |
$ |
17,047,922 |
|
| Issuance of stock-based compensation |
|
142,568 |
|
|
1,426 |
|
|
96,074 |
|
|
— |
|
|
— |
|
|
97,500 |
|
| Compensation expense related to stock options |
|
— |
|
|
— |
|
|
254,053 |
|
|
— |
|
|
— |
|
|
254,053 |
|
| Compensation related to restricted stock |
|
— |
|
|
— |
|
|
329,957 |
|
|
— |
|
|
— |
|
|
329,957 |
|
| Forfeiture of unvested restricted stock |
|
— |
|
|
— |
|
|
1,666,299 |
|
|
— |
|
|
(1,666,299 |
) |
|
— |
|
| Net loss |
|
— |
|
|
— |
|
|
— |
|
|
(807,078 |
) |
|
— |
|
|
(807,078 |
) |
| BALANCE, MARCH 31, 2026 |
|
49,933,502 |
|
$ |
499,335 |
|
$ |
54,795,722 |
|
$ |
(32,823,910 |
) |
$ |
(5,548,793 |
) |
$ |
16,922,354 |
|
Three Months Ended March 31, 2025
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
Additional |
|
|
|
|
|
Total |
|
| |
|
Common Stock |
|
Paid-in |
|
Accumulated |
|
Treasury |
|
Stockholders’ |
|
| |
|
Shares |
|
Amount |
|
Capital |
|
Deficit |
|
Stock |
|
Equity |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BALANCE, DECEMBER 31, 2024 |
|
49,377,617 |
|
$ |
493,776 |
|
$ |
49,581,303 |
|
$ |
(29,378,906 |
) |
$ |
(3,882,494 |
) |
$ |
16,813,679 |
|
| Issuance of stock-based compensation |
|
183,881 |
|
|
1,839 |
|
|
95,661 |
|
|
— |
|
|
— |
|
|
97,500 |
|
| Compensation expense related to stock options |
|
— |
|
|
— |
|
|
359,197 |
|
|
— |
|
|
— |
|
|
359,197 |
|
| Compensation related to restricted stock |
|
— |
|
|
— |
|
|
227,860 |
|
|
— |
|
|
— |
|
|
227,860 |
|
| Issuance of warrants |
|
— |
|
|
— |
|
|
13,032 |
|
|
— |
|
|
— |
|
|
13,032 |
|
| Net loss |
|
— |
|
|
— |
|
|
— |
|
|
(1,166,237 |
) |
|
— |
|
|
(1,166,237 |
) |
| BALANCE, MARCH 31, 2025 |
|
49,561,498 |
|
$ |
495,615 |
|
$ |
50,277,053 |
|
$ |
(30,545,143 |
) |
$ |
(3,882,494 |
) |
$ |
16,345,031 |
|
- 6 -
Table of Contents
KORU MEDICAL SYSTEMS, INC.
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
NOTE 1 — NATURE OF OPERATIONS AND SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
NATURE OF OPERATIONS
KORU MEDICAL SYSTEMS, INC. (the “Company,”
“KORU Medical,” “KORU,” “we,” “us” or “our”) develops, manufactures and commercializes
innovative and patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed
by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for
quality system management. The Company operates as one segment.
BASIS OF PRESENTATION
The accompanying financial statements should be read
in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2025 (“Annual Report”).
In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has
omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited financial statements of the Company.
The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary
for a fair statement of the Company’s financial position, results of operations, and cash flows for the periods presented. All
such adjustments are of a normal, recurring nature. The Company’s results of operations and cash flows for the interim periods
are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.
CASH AND CASH EQUIVALENTS
For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. As of March
31, 2026 the Company held cash and cash-equivalents of $8.8 million, the majority of which was held in a secured US-treasury money market
fund.
PATENTS
Costs incurred in obtaining patents have been capitalized
and are being amortized over the legal life of the patents.
STOCK-BASED COMPENSATION
The Company maintains an omnibus equity incentive
plan under which it grants options and other equity incentive awards to certain executives, employees and consultants, as well as shares
of common stock to non-employee directors.
The fair value of each stock option grant is estimated
on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value.
The entire compensation expense of the award is recognized over the vesting period.
Shares of stock granted for director fees are recorded
at the fair value of the shares at the grant date.
Restricted stock awards are equity classified and
measured at the fair market value of the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain
market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value
of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock price. The fair value of restricted
stock awards vesting at certain annual sales growth thresholds were estimated as of the date of Board acknowledgement of the achievement,
at the current stock price. We recognize restricted stock expense using the straight-line attribution method over the requisite service
period and account for forfeitures as they occur.
Restricted stock units (“RSUs”) and performance
stock units (“PSUs”) are equity classified and measured at the fair market value of the underlying stock at the grant date.
NET LOSS PER SHARE
The Company computes net loss per share using the
weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the
conversion, exercise or issuance of all potential common stock equivalents, which comprise the Company’s outstanding common stock
options, unvested restricted stock units, performance stock units and warrants, would be anti-dilutive, due to the reporting of a net
loss for each of the periods in the accompanying statements of operations.
USE OF ESTIMATES IN THE FINANCIAL STATEMENTS
The preparation of financial statements in conformity
with United States generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Important estimates include but are not limited to asset lives, deferred tax valuation allowances, inventory valuation, expected credit
losses, and customer rebate and incentive accruals. The results of operations for the three months ended March 31, 2026 are not necessarily
indicative of the results that may be expected for the entire 2026 fiscal year.
REVENUE RECOGNITION
Our revenues are derived from three business sources:
(i) domestic core (which consists of US and Canada), (ii) international core, and (iii) pharma services and clinical trials. Our
domestic and international core revenues consist of sales of our syringe drivers, tubing and needles (“Product Revenue”) for
the delivery of subcutaneous drugs that are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin
to treat Primary Immunodeficiency Diseases (“PIDD”) and Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”).
Pharma services and clinical trials consist of Product Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II,
Phase III) of biopharmaceutical companies in the drug development process as well as non-recurring engineering services (“NRE”)
revenues (including testing and registration services) received from biopharmaceutical companies to ready or customize the FREEDOMTM
System for clinical and commercial use across multiple drug categories.
For Product Revenue, we recognize revenues when shipment
occurs, at which point the customer obtains control and ownership of the goods. Shipping costs generally are billed to customers
and are included in Product Revenue.
The Company generally does not accept return of goods
shipped unless it is a Company error. The only credits provided to customers are for defective merchandise. The Company warrants
the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation.
The costs under the warranty are expensed as incurred.
Rebates are provided to distributors for the difference
in selling price to distributors and pricing specified to select customers. In addition, rebates are provided to customers for meeting
growth targets. Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded
as a reduction of revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.
We recognize NRE revenue under an input method, which
recognizes revenue on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time
elapsed) to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance
obligation (i.e. completion milestone). The input method that we use is based on costs incurred.
Contracts are often modified to account for changes
in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing,
enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered
to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations,
the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized
as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily
represent revenue earnings over time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred
revenue) consist of fees invoiced or paid by the Company’s customers for which the associated performance obligations have not been
satisfied and revenue has not been recognized based on the Company’s revenue recognition criteria described above. The Company has
recognized a contract asset, which is included in other receivables in the accompanying balance sheet, of $335,206 and $319,955 as of
March 31, 2026 and December 31, 2025, respectively.
The following table summarizes net revenues from our
distributors and direct customers by geography for the three months ended March 31, 2026, and 2025.
| |
|
Three Months Ended March 31, |
|
| |
|
2026 |
|
2025 |
|
| Revenues |
|
|
|
|
|
|
|
| Domestic |
|
$ |
8,438,743 |
|
$ |
7,205,633 |
|
| International |
|
|
3,325,881 |
|
|
2,429,442 |
|
| Total |
|
$ |
11,764,624 |
|
$ |
9,635,075 |
|
ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED
The Company considers the applicability and impact
of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures
are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.
IMPAIRMENT OF LONG-LIVED ASSETS
The Company reviews long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment
loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. The Company did not record any impairment losses for the quarter ended March 31,
2026, nor March 31, 2025.
NOTE 2 — PROPERTY AND EQUIPMENT
Property and equipment consist of the following at:
| |
|
March 31, 2026 |
|
December 31, 2025 |
|
| |
|
|
|
|
|
|
|
| Furniture and office equipment |
|
$ |
1,390,946 |
|
$ |
1,407,636 |
|
| Leasehold improvements |
|
|
1,959,045 |
|
|
1,959,045 |
|
| Manufacturing equipment and tooling |
|
|
5,199,410 |
|
|
5,171,898 |
|
| Total property and equipment |
|
|
8,549,401 |
|
|
8,538,579 |
|
| Less: accumulated depreciation and amortization |
|
|
(4,213,519 |
) |
|
(4,067,193 |
) |
| Property and equipment, net |
|
$ |
4,335,882 |
|
$ |
4,471,386 |
|
NOTE 3 — STOCK-BASED COMPENSATION
The Company maintains three equity incentive plans: the 2015 Stock Option
Plan, as amended (the “2015 Plan”), the 2021 Omnibus Equity Incentive Plan (the “2021 Plan”), and the 2024 Omnibus
Equity Incentive Plan (the “2024 Plan”). All equity awards issued to employees, consultants, and non-employee directors on
or after May 9, 2024, are issued from the 2024 Plan. The Company has also issued restricted stock and stock options as employment inducement
awards outside of these plans to certain executive officers.
The 2015 Plan provides for the grant of incentive
stock options and nonqualified stock options. As of March 31, 2026, there were 1,958,000 shares reserved for outstanding awards
under the 2015 Plan.
The 2021 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units, performance share units, stock
appreciation rights, and/or other equity-based awards to employees, consultants and directors. As of March 31, 2026, there were 100,000 shares
reserved for outstanding awards under the 2021 Plan.
The 2024 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units, performance share units, stock
appreciation rights and/or other equity-based awards to employees, consultants and directors. Awards previously made under the 2015 Plan
and the 2021 Plan that are forfeited or cancelled after May 9, 2024 will be available for issuance under the 2024 Plan. As of March 31,
2026, there were 2,085,495 shares reserved for outstanding awards and 780,131 shares available for issuance under
the 2024 Plan.
Each non-employee director of the Company (other than
the Chairman of the Board) is eligible to receive $110,000 annually, to be paid quarterly in arrears of $12,500 in cash and
$15,000 in common stock. The Chairman of the Board is eligible to receive $140,000 annually, to be paid quarterly
in arrears of $12,500 in cash and $22,500 in common stock. All payments were and are pro-rated for partial service.
Restricted stock units (“RSUs”) and performance
share units (“PSUs”) are equity classified and measured at the fair value of the underlying stock at the grant date.
Shares of stock granted for non-employee director
fees are recorded at the fair value of the shares at the grant date.
On March 12, 2026 the Company announced the retirement
of our CEO, Linda Tharby, with both parties entering into a separation and transition agreement, and general release. Ms. Tharby
will continue to serve as CEO through June 30, 2026, at which time she will transition to a non-executive advisory employee, and continue
to serve as a member of the Board of Directors through December 31, 2026. As part of the separation and transition agreement, 380,000
unvested restricted stock awards from Ms. Tharby’s new hire inducement plan were forfeited during the three months ended March 31,
2026. Additional unvested restricted stock awards, RSUs, PSUs, and stock options will be forfeited upon her transition to non-executive
advisory employee status on June 30, 2026. All forfeited restricted stock awards will be transferred to Treasury, and forfeited
RSUs, PSUs, and stock options will be remitted back to the 2024 Plan.
Time-Vesting Stock Options
The following table summarizes the status of the time-vested
stock options outstanding at March 31, 2026:
Schedule of status of time based stock options
| |
|
Shares |
|
Weighted
Average
Exercise
Price |
|
| |
|
|
|
|
|
| Outstanding at January 1 |
|
3,120,178 |
|
$ |
3.25 |
|
| Granted |
|
494,067 |
|
|
4.99 |
|
| Exercised |
|
— |
|
|
— |
|
| Forfeited |
|
— |
|
|
— |
|
| Outstanding at March 31 |
|
3,614,245 |
|
$ |
3.46 |
|
| Options exercisable at March 31 |
|
1,951,226 |
|
$ |
3.34 |
|
Total stock-based compensation expense for time-vested
stock options, included in operating expense in the accompanying statement of operations, was $254,053 for the three months ended
March 31, 2026. No cash was received from option exercises for the three months ended March 31, 2026. As of March 31, 2026,
the intrinsic value of all time-based stock options was $3,479,147.
The following table presents information pertaining
to time-vested stock options outstanding at March 31, 2026:
Schedule of information pertaining to options outstanding
| Range of Exercise Price |
|
Number
Outstanding |
|
Weighted
Average
Remaining
Contractual
Life |
|
Weighted
Average
Exercise
Price |
|
Number
Exercisable |
|
Weighted
Average
Exercise
Price |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| $2.08-$5.70 |
|
3,614,245 |
|
7.2 years |
|
$ |
3.46 |
|
1,951,226 |
|
$ |
3.34 |
|
As of March 31, 2026, there was $3,419,986 of
total unrecognized compensation cost related to unvested share-based stock compensation awards granted under the Plans. That cost
is expected to be recognized over a weighted-average period of 26 months.
Restricted Stock Awards, RSUs, and PSUs
The following table summarizes the activities for
our unvested restricted stock awards, RSUs, and PSUs for the three months ended March 31, 2026.
| |
|
Shares |
|
Weighted
Average
Grant-Date
Fair Value |
|
| |
|
|
|
|
|
| Unvested at January 1 |
|
1,722,147 |
|
$ |
2.99 |
|
| Granted |
|
673,801 |
|
$ |
4.81 |
|
| Vested |
|
(171,599 |
) |
$ |
2.32 |
|
| Forfeited/canceled |
|
(150,000) |
|
|
3.31 |
|
| Unvested at March 31 |
|
2,074,349 |
|
$ |
3.61 |
|
During the three months ended March 31, 2026, 380,000
shares of restricted stock originally issued to our CEO as part of her new hire inducement award were forfeited and returned to treasury,
inclusive of the 150,000 shares noted above due to a catch-up provision which was not achieved.
Total stock-based compensation expense for restricted
stock awards, RSUs, and PSUs, included in operating expense in the accompanying statement of operations, was $329,957 for the three months
ended March 31, 2026.
As of March 31, 2026, there was $5,494,834 of unrecognized
compensation cost related to unvested employee restricted stock awards, RSUs, and PSUs. This amount is expected to be recognized over
a weighted-average period of 27 months.
NOTE 4 — DEBT OBLIGATIONS
On March 8, 2024, the Company entered into a loan
and security agreement with a large domestic banking institution, as lender, providing for a $5,000,000 revolving credit facility and
a $5,000,000 term loan facility. Borrowings are secured by a first-priority lien on substantially all of the assets of the Company, subject
to customary exceptions. On March 30, 2026 the loan and security agreement was amended to extend the maturity of the $5,000,000 revolver
from December 31, 2026 to March 30, 2028, and extends the interest-only period of the $5,000,000 term loan from September 30, 2026 to
June 30, 2027 with a possible further extension to December 31, 2027 upon the achievement of certain EBITDA milestones as set forth therein.
The term loan maturity has been extended from December 1, 2028 to December 1, 2029. The amendment lowers the interest rate floor to 5.50%
from 6.50% for the revolver and the term loan. The amendment removes the adjusted quick ratio covenant for both the term loan and the
revolver. The adjusted quick ratio covenant for the revolver has been replaced with a remaining months liquidity covenant of at least
twelve months, to be tested monthly beginning the first month the revolver is drawn on; provided, however, the Company will be in compliance
if trailing three (3) month average Adjusted EBITDA (as defined in the revolver) is positive.
NOTE 5 — LEASES
We have finance and operating leases for our corporate
office, vehicles, and certain office and computer equipment.
The components of lease expense were as follows:
| |
|
|
|
|
|
|
| |
|
Three Months Ended |
|
| |
|
March 31, |
|
| |
|
2026 |
|
2025 |
|
| |
|
|
|
|
|
|
|
| Operating lease cost |
|
$ |
133,495 |
|
$ |
125,084 |
|
| Short-term lease cost |
|
|
4,700 |
|
|
3,386 |
|
| Total lease cost |
|
$ |
138,195 |
|
$ |
128,470 |
|
| |
|
|
|
|
|
|
|
| Finance lease cost: |
|
|
|
|
|
|
|
| Amortization of right-of-use assets |
|
$ |
29,474 |
|
$ |
28,896 |
|
| Interest on lease liabilities |
|
|
2,155 |
|
|
4,490 |
|
| Total finance lease cost |
|
$ |
31,629 |
|
$ |
33,386 |
|
Supplemental cash flow information related to leases
was as follows:
| |
|
|
|
|
|
|
| |
|
Three Months Ended |
|
| |
|
March 31, |
|
| |
|
2026 |
|
2025 |
|
| Cash paid for amounts included in the measurement of lease liabilities: |
|
|
|
|
|
|
|
| Operating cash flows from operating leases |
|
$ |
132,985 |
|
$ |
129,363 |
|
| Financing cash flows from finance leases |
|
|
32,859 |
|
|
32,859 |
|
| |
|
March 31,
2026 |
|
December 31,
2025 |
|
| Weighted Average Remaining Lease Term |
|
|
|
|
|
| Operating leases |
|
6.32 Years |
|
6.57 Years |
|
| Finance leases |
|
1.43 Years |
|
1.67 Years |
|
| |
|
|
|
|
|
| Weighted Average Discount Rate |
|
|
|
|
|
| Operating leases |
|
4.12% |
|
4.13% |
|
| Finance leases |
|
4.77% |
|
4.74% |
|
Maturities of lease liabilities are as follows:
| Year Ended December 31, |
|
Operating Leases |
|
Finance Leases |
|
| Remainder of 2026 |
|
$ |
451,494 |
|
$ |
98,578 |
|
| 2027 |
|
|
554,475 |
|
|
74,194 |
|
| 2028 |
|
|
557,286 |
|
|
6,178 |
|
| 2029 |
|
|
553,759 |
|
|
— |
|
| 2030 |
|
|
568,217 |
|
|
— |
|
| Thereafter |
|
|
986,164 |
|
|
— |
|
| Total undiscounted lease payments |
|
|
3,671,395 |
|
|
178,950 |
|
| Less: imputed interest |
|
|
(478,553 |
) |
|
(6,067 |
) |
| Total lease liabilities |
|
$ |
3,192,842 |
|
$ |
172,883 |
|
NOTE 6 — INCOME TAXES
For interim income tax reporting, the Company estimates
its annual effective tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete
items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense
of zero for the three months ended March 31, 2026, and 2025, which is lower than the statutory tax rate at 21% primarily due to the valuation
allowance established against the net deferred tax assets.
We evaluate our deferred tax assets to determine if
they are more likely than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income
Taxes. After considering our cumulative pretax loss (the three-year period ended with the current year), as well as analyzing all
available evidence, we maintained the full valuation allowance against our net deferred tax assets. As we continue to assess
the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction of the
valuation allowance in future periods.
The Company files income tax returns in the U.S. federal
jurisdiction and in various state jurisdictions. Income tax returns for years prior to fiscal 2022 are no longer subject to examination
by tax authorities.
NOTE 7 — COMMITMENTS AND CONTINGENCIES
LEGAL PROCEEDINGS
The Company has been and may again become involved
in legal proceedings, claims and litigation arising in the ordinary course of business. The Company is not presently a party to
any litigation or other legal proceedings that is believed to be material to its financial condition.
NOTE 8 — SUBSEQUENT EVENTS
On April 12, 2026, 200,000 shares of unvested restricted stock originally
issued to our CEO as part of her new hire inducement award were forfeited and returned to treasury.
- 12 -
Table of Contents
PART I — ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Quarterly Report on Form 10-Q contains, and our
officers and representatives may from time to time make, certain “forward-looking” statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management,
as well as assumptions made and information currently available. Forward-looking statements are neither historical facts nor assurances
of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking
statements relate to the future, they are subject to uncertainties, risks and changes in circumstances that are difficult to predict and
many of which are outside of our control.
Our actual results may vary materially from the forward-looking
statements made in this report due to important factors such as uncertainties associated with inflation, tariffs, war and other geopolitical
conflicts, customer ordering patterns, availability and costs of raw materials and labor and our ability to recover such costs, future
operating results, growth of new patient starts and the Ig market, our compliance with Food and Drug Administration and foreign authority
regulations and the outcome of regulatory audits, introduction and adoption of competitive products, acceptance of and demand for new
and existing products, ability to penetrate new markets, success in enforcing and obtaining patents, reimbursement related risks, government
regulation of the home health care industry, success of our research and development effort, expanding the market of FREEDOMTM
System, demand in the SCIg market, availability of sufficient capital if or when needed, dependence on key personnel, and the impact of
recent accounting pronouncements, as well as those risks and uncertainties described in our Annual Report on Form 10-K for the year ended
December 31, 2025. When used in this report, the words “estimate,” “project,” “believe,” “may,”
“will,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify
forward-looking statements, which include, without limitation, statements regarding need for additional financing. Such statements
reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties
that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake
any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
Throughout this report, the “Company,”
“KORU Medical,” “we,” “us” or “our” refers to KORU Medical Systems, Inc.
OVERVIEW
The Company develops, manufactures and markets proprietary
portable and innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and
Drug Administration (the “FDA”) quality and regulatory system and international regulations and standards for quality system
management.
Our revenues derive from three business sources: (i)
domestic core (which consists of US and Canada), (ii) international core, and (iii) pharma services and clinical trials. Our domestic
core and international core revenues consist of sales of our products for the delivery of subcutaneous drugs that are FDA cleared for
use with the FREEDOMTM System, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency Diseases (“PIDD”)
and Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”). Pharma services and clinical trials revenues consist of product
revenues from our infusion system (syringe drivers, tubing and needles) for feasibility/clinical trials (pre-clinical studies, Phase I,
Phase II, Phase III) of biopharmaceutical companies in the drug development process as well as non-recurring engineering services revenues
(“NRE”) received from biopharmaceutical companies to ready or customize the FREEDOMTM System for clinical and commercial
use.
The Company ended the first quarter of 2026 with $11.8
million in net revenues, a 22.1% increase compared to $9.6 million in the same period last year. Revenues were driven by growth in our
core domestic and international business of 11.7% and 35.2%, respectively, along with an increase of 166.0% in our pharma services and
clinical trials business.
Gross profit for the first quarter of 2026 was $7.2
million, a 19.6% increase compared to $6.0 million in the same period last year, primarily driven by volume growth. Gross margin was 61.5%
for the three months ended March 31, 2026, a decrease from 62.8% in the prior year period. We define gross margin as gross profit stated
as a percentage of net revenues.
Operating expenses for the first quarter of 2026 were
$8.1 million, compared to $7.3 million for the same period last year, driven by an increase of $0.6 million in selling, general, and administrative
expenses, and an increase of $0.2 million in research and development expenses.
- 13 -
Table of Contents
The Company imports certain materials and products
that are subject to U.S. government tariffs and import duties. On February 20, 2026, a US federal court ordered the U.S. government to
begin refunding certain tariffs. The Company believes that some of the tariffs it has paid may be eligible for refund; however, the amount
and timing of any potential refunds are uncertain. Accordingly, the Company has not recorded, nor plans to record, any benefit related
to possible tariff refunds at this time.
RESULTS OF OPERATIONS
Three months ended March 31, 2026, compared to
March 31, 2025
Net Revenues
The following table summarizes our net revenues for
the three months ended March 31, 2026, and 2025:
| |
|
Three Months Ended March 31, |
|
Change from Prior Year |
|
% of Net Revenues |
|
| |
|
2026 |
|
2025 |
|
$ |
|
% |
|
2026 |
|
2025 |
|
| Net Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Domestic Core |
|
$ |
7,739,872 |
|
$ |
6,927,964 |
|
$ |
811,908 |
|
11.7% |
|
65.8% |
|
71.9% |
|
| International Core |
|
|
3,284,041 |
|
|
2,428,662 |
|
|
855,379 |
|
35.2% |
|
27.9% |
|
25.2% |
|
| Total Core |
|
|
11,023,913 |
|
|
9,356,626 |
|
|
1,667,287 |
|
17.8% |
|
93.7% |
|
97.1% |
|
| Pharma Services and Clinical Trials |
|
|
740,711 |
|
|
278,449 |
|
|
462,262 |
|
166.0% |
|
6.3% |
|
2.9% |
|
| Total |
|
$ |
11,764,624 |
|
$ |
9,635,075 |
|
$ |
2,129,549 |
|
22.1% |
|
100% |
|
100% |
|
Total net revenues increased $2.1 million, or 22.1%,
to $11.8 million for the three months ended March 31, 2026, as compared to $9.6 million in the prior year period. Domestic core revenues
were $7.7 million, an increase of 11.7% over the prior year period, primarily due to higher consumable volumes, driven by new patient
starts and market share gains within new and existing accounts, supported by a strong underlying SCIg market. International core revenues
were $3.3 million, an increase of 35.2% over the prior year period, primarily due to higher pump and consumable volumes, driven by distributor
purchases supporting pre-filled syringe (PFS) conversions for a key EU market. Pharma services and clinical trials net revenues were $0.7
million, an increase of 166.0% over the prior year period, primarily due to higher clinical trial product revenues for advancing existing
collaborations.
Gross Profit
Our gross profit for the three months ended March
31, 2026 and 2025 is as follows:
| |
|
Three Months Ended March 31, |
|
Change from Prior Year |
|
| |
|
2026 |
|
2025 |
|
$ |
|
% |
|
| Gross Profit |
|
$ |
7,231,389 |
|
$ |
6,046,335 |
|
$ |
1,185,054 |
|
19.6% |
|
| Gross Margin |
|
|
61.5% |
|
|
62.8% |
|
|
|
|
|
|
Gross profit increased $1.2 million, or 19.6%, to $7.2 million in the three
months ended March 31, 2026, as compared to $6.0 million in the prior year period, primarily driven by volume growth. Gross margin decreased
to 61.5% in the three months ended March 31, 2026, as compared to 62.8% in the prior year period. The decrease in gross margin was primarily
driven by higher production costs based on timing of production runs in the prior quarter that were amortized in the three months ended
March 31, 2026, and tariff-related charges that did not occur in the prior year period, partially offset by a favorable geographic sales
mix.
Operating Expenses
Our selling, general and administrative, research
and development and depreciation and amortization expenses for the three months ended March 31, 2026 and 2025 are as follows:
| |
|
Three Months Ended March 31, |
|
Change from Prior Year |
|
| |
|
2026 |
|
2025 |
|
$ |
|
% |
|
| Selling, general and administrative |
|
$ |
6,582,178 |
|
$ |
5,959,374 |
|
$ |
622,804 |
|
10.5% |
|
| Research and development |
|
|
1,316,603 |
|
|
1,114,609 |
|
|
201,994 |
|
18.1% |
|
| Depreciation and amortization |
|
|
197,531 |
|
|
217,357 |
|
|
(19,826 |
) |
(9.1% |
) |
| Total Operating Expenses |
|
$ |
8,096,312 |
|
$ |
7,291,340 |
|
$ |
804,972 |
|
11.0% |
|
- 14 -
Table of Contents
Selling, general and administrative expenses increased
$0.6 million, or 10.5%, to $6.6 million during the three months ended March 31, 2026, as compared to $6.0 million in the prior year period.
The increase in selling, general and administrative expenses was primarily driven by increases in legal fees and compensation expenses
related to salary and stock compensation, partially offset by lower temporary labor expenses.
Research and development expenses increased $0.2 million,
or 18.1%, to $1.3 million during the three months ended March 31, 2026, as compared to $1.1 million in the prior year period, primarily
due to higher compensation expenses for salary and stock compensation related to headcount additions, partially offset by lower temporary
labor expenses.
Depreciation and amortization expense remained flat
at $0.2 million during the three months ended March 31, 2026, as compared to $0.2 million in the prior year period.
Net Loss
| |
|
Three Months Ended March 31, |
|
Change from Prior Year |
|
| |
|
2026 |
|
2025 |
|
$ |
|
% |
|
| Net Loss |
|
$ |
(807,078 |
) |
$ |
(1,166,237 |
) |
$ |
359,159 |
|
30.8% |
|
Our net loss decreased $0.4 million in the three months
ended March 31, 2026, as compared to the prior year period, primarily driven by an increase in gross profit of $1.2 million, driven by
increased revenues, partially offset by operating expense increases of $0.8 million.
LIQUIDITY AND CAPITAL RESOURCES
Our principal source of liquidity is our cash on hand
of $8.8 million as of March 31, 2026. Our principal source of operating cash inflows is from sales of our products and NRE. Our
principal cash outflows relate to the purchase and production of inventory, funding of research and development, and selling, general
and administrative expenses. To develop new products, support future growth, achieve operating efficiencies, and maintain product quality,
we are continuing to invest in research and development and manufacturing equipment.
Our inventory position was $4.5 million at March 31,
2026, which reflects an increase of $0.8 million from December 31, 2025, due to expected future demand from our customers.
We expect that our cash on hand, cash flows from operations,
and as needed, cash available under our credit facility, will be sufficient to meet our requirements at least through the next twelve
months. Continued execution on our longer-term strategic plan may require the Company to draw on our credit facility, take on additional
debt, raise capital through issuance of equity, or utilize a combination of the above. Our future capital requirements may vary from those
currently planned and will depend on many factors, including our rate of sales growth, the timing and extent of spending on various strategic
initiatives including research and development, our international expansion, the timing of new product introductions, market acceptance
of our solutions, and overall economic conditions including inflation and the potential impact of global supply imbalances on the global
financial markets. To the extent that current and anticipated future sources of liquidity are or are expected to be insufficient to fund
our future business activities and requirements, we may be required to draw on our new credit facility or seek additional equity or debt
financing sooner. There can be no assurance the Company will be able to obtain the financing or raise the capital required to fund operations or planned expansion.
Credit Facility
On March 8, 2024, the Company entered into a loan
and security agreement with a large domestic banking institution, as lender, providing for a credit facility consisting of a $5,000,000
revolving credit facility and a $5,000,000 term loan facility. On March 30, 2026, the Company entered into an amendment to the agreement
extending the revolver maturity to March 30, 2028 and the term loan maturity to December 1, 2029, extending the interest-only period on
the term loan through at least June 30, 2027, and lowering the interest rate floor on both facilities from 6.50% to 5.50%. The Company
has not drawn on the credit facility, and there is no obligation to do so at any time. Borrowings are secured by a first-priority lien
on substantially all of the assets of the Company, subject to customary exceptions. The credit facility contains customary affirmative
and negative covenants and events of default. For a complete description of the terms of the credit facility, see Note 4 to the condensed
financial statements included herein.
- 15 -
Table of Contents
Cash Flows
The following table summarizes our cash flows:
| |
|
Three Months Ended
March 31, 2026 |
|
Three Months Ended
March 31, 2025 |
|
| Net cash from/(used in) operating activities |
|
$ |
14,663 |
|
$ |
(237,467 |
) |
| Net cash used in investing activities |
|
$ |
(89,885 |
) |
$ |
(446,838 |
) |
| Net cash used in financing activities |
|
$ |
(29,216 |
) |
$ |
(160,808 |
) |
Operating Activities
Net cash from operating activities was $0.01 million
for the three months ended March 31, 2026, as compared to $(0.2) million in the prior year period. This net cash inflow of $0.01 million
was primarily due to the net loss of $0.8 million, an increase in inventory of $0.8 million, offset by higher accounts payable of $0.4
million, higher accrued expenses of $0.2 million, and lower accounts receivable of $0.2 million. Additional offsets to the net loss were
non-cash items including stock-based compensation expense of $0.7 million, and depreciation and amortization expense of $0.2 million.
Net cash used in operating activities was $0.2 million
for the three months ended March 31, 2025, as compared to $0.3 million in the prior year period. This net cash usage of $0.2 million
was primarily due to the net loss of $1.2 million, an increase in accounts receivable of $0.2 million, and increases in inventory of $0.5
million, partially offset by increases in accounts payable of $0.4 million, expense and payroll related accruals of $0.3 million, and
other liabilities of $0.1 million. Additional offsets to the net loss were non-cash items including stock-based compensation expense of
$0.7 million, and depreciation and amortization expense of $0.2 million.
Investing Activities
Net cash used in investing activities of $0.1 million
for the three months ended March 31, 2026, was for capital expenditures for manufacturing equipment related to our new infusion pump
production line.
Net cash used in investing activities of $0.4 million
for the three months ended March 31, 2025, was for capital expenditures for manufacturing equipment related to our new consumables production
lines.
Financing Activities
Net cash used in financing activities of $0.03 million
for the three months ended March 31, 2026 was due to payments for our finance leases.
Net cash used in financing activities of $0.2 million
for the three months ended March 31, 2025 was due primarily to payments on our note payable for insurance premium financing.
ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED
Refer to “NOTE 1 — NATURE OF OPERATIONS
AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES” in the accompanying financial statements, which is incorporated herein by reference.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
Not applicable.
- 16 -
Table of Contents
ITEM 4. CONTROLS AND PROCEDURES
The Company’s management, including the Company’s
Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls
and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of
the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of
ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the
Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods
specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its
Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
There have been no changes in the Company’s
internal control over financial reporting during the three months ended March 31, 2026, that have materially affected, or are reasonably
likely to materially affect, the Company’s internal control over financial reporting.
PART II – OTHER INFORMATION
ITEM 1A. RISK FACTORS
Our operations and financial results are subject to
various risks and uncertainties, including those described in “PART 1, ITEM 1A. RISK FACTORS” in our Annual Report on Form
10-K for the year ended December 31, 2025, which could adversely affect our business, financial condition, results of operations, cash
flows, and the trading price of our common stock.
PART II – ITEM 6. EXHIBITS.
| Exhibit No. |
Description |
| |
|
| 31.1 |
Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002 |
| |
|
| 31.2 |
Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002 |
| |
|
| 32.1 |
Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002 |
| |
|
| 32.2 |
Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002 |
| |
|
| 101.INS |
Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| |
|
| 101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
| |
|
| 101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| |
|
| 101.DEF |
Inline XBRL Taxonomy Definition Linkbase Document |
| |
|
| 101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
| |
|
| 101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| |
|
| 104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
- 17 -
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
KORU MEDICAL SYSTEMS, INC. |
| |
|
| May 6, 2026 |
/s/ Linda Tharby |
| |
Linda Tharby, Chief Executive Officer
(Principal Executive Officer) |
| |
|
| May 6, 2026 |
/s/ Thomas Adams |
| |
Thomas Adams, Chief Financial Officer and Treasurer
(Principal Financial Officer) |
- 18 -
